Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA's Drug Seizures Seen As Most Significant Aspect Of Stem Cell Crackdown

Executive Summary

Former Office of Compliance and Biologics Quality Deputy Director Mark Schwartz says dishonest players have not often seen serious enforcement actions from the agency.

You may also be interested in...

CBER Director Marks: Regenerative Medicine Enforcement Will Be 'Notched Up' In 2018

In an interview with the Pink Sheet, Marks said the guidances on regenerative medicines make clear what the agency will be enforcing.

Australia To Bring Complex Stem Cell Therapies Within Regulatory Fold

Taking cue from the regulators in the US and the EU, the Australian government is developing a policy to formally regulate the increasingly complex field of stem cell therapies. The new regulatory approach is to be supported by detailed guidance from the Therapeutic Goods Administration to help legitimate products gain approval.

Crackdown On Bad Regenerative Medicine Could Benefit Gene Therapy

US FDA to offer series of guidances on regenerative product development – and declares gene therapies eligible for RMAT – as enforcement against 'unscrupulous actors' continues.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts